Latest Trading Halts News

Arrow Minerals revealed a previously confidential tenement acquisition following an ASX price query triggered by a sharp rise in its share price. The company attributes the price movement to multiple positive developments rather than the acquisition itself.

Australis Oil & Gas (ASX: ATS) has confirmed no undisclosed price-sensitive information following a recent uptick in its share price and volume, attributing market activity to development progress in the Tuscaloosa Marine Shale.

Viridis Mining and Minerals Limited (ASX: VMM) has halted trading of its shares pending the release of its Definitive Feasibility Study results, with the suspension expected to last until 20 August 2026 or earlier if the announcement is made sooner.

Rubik Australia has officially acquired 100% of Qube Holdings shares through a scheme of arrangement, with Qube set to be delisted from the ASX on 17 August 2026.

Dateline Resources faces a US court injunction halting operations at its Colosseum Project, while ASX suspends and then reinstates trading over disclosure timing concerns.

Altech Batteries has officially ended its CERENERGY battery project and terminated its strategic partner search, responding to ASX queries about the timing of its disclosures following an unauthorized announcement by a related entity.

American Tungsten & Antimony Ltd (ASX: AT4) affirmed the materiality of its US acquisition deal and detailed its adherence to ASX continuous disclosure rules following an ASX inquiry.

Heavy Rare Earths Limited (ASX:HRE) has secured $2.028 million through a placement and entitlement offer to advance drilling programs and a strategic review across its key projects in South Australia and Western Australia.

Sky Metals has voluntarily suspended its ASX-listed securities pending a material announcement regarding its Tallebung Tin-Tungsten-Silver Project, with trading expected to resume by 10 August or upon release of the news.

Environmental Clean Technologies (ASX: ECT) disclosed confidential talks on acquiring Xenica Materials and a new engineering deal with Metallium amid a price surge, followed by a $12 million placement announcement.

Neurotech International has secured FDA clearance for its NTI164 Investigational New Drug application and obtained Notices of Allowance for two US patents, advancing its Phase 3 autism spectrum disorder program.

ClearView Wealth’s acquisition by Zurich Financial Services Australia has cleared its final legal hurdle, triggering a trading halt and scheduled shareholder payouts including a special dividend and cash scheme consideration.